Larry Zhang

Mr. Zhang joined CASI Pharmaceuticals in September 2018 as President of CASI Pharmaceuticals (Beijing) Co., Ltd., which is a subsidiary of CASI Pharmaceuticals, and became President of CASI Pharmaceuticals in September 2019. Mr. Zhang has more than 20 years of management experience in the healthcare and biopharmaceutical industries in the U.S., Asia Pacific, and China. Prior to joining CASI’s Beijing office, Mr. Zhang was Vice President, Head of Public Affairs and Corporate Responsibility at Novartis Group (China), where he focused on the public affairs/public relations strategy, including initiating Novartis’ China policy focusing on China FDA (NMPA) new drug approval reform, intellectual property protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011-2016, he was Chief Executive Officer of Sandoz Pharmaceutical (China), a Novartis Company. Mr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific. He holds bachelor and master degrees in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.